Hillsdale Investment Management Inc. Aeterna Zentaris Inc. Transaction History

Hillsdale Investment Management Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 02, 2019	SELL	$2.04 - $5.43 $128,724 - $342,633	-63,100 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$3.03 - $4.65 $111,807 - $171,585	36,900 Added 140.84%	63,100 $296,000
Q4 2018 Feb 12, 2019	BUY	$1.3 - $3.87 $34,060 - $101,394	26,200 New	26,200 $77,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $26.8M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.